947144-38-9

Upstream product

• 947144-53-8 4-chloro-3-nitro-6-trifluoromethyl-1H-pyridin-2-one 
• 100-46-9 benzylamine 
• 947144-26-5 4-hydroxy-3-nitro-6-trifluoromethyl-1H-pyridin-2-one 
• 947144-32-3 4-hydroxy-6-(trifluoromethyl)pyridin-2(1H)-one 
• 947144-53-8 4-chloro-3-nitro-6-(trifluoromethyl)pyridin-2-ol 

Downstream Products

• 947144-18-5 benzyl-(2-chloro-3-nitro-6-trifluoromethylpyridin-4-yl)amine 
• 947143-87-5 benzyl-(2,3-diamino-6-trifluoromethylpyridin-4-yl)carbamic acid ethyl ester 
• 947142-81-6 4-amino-1-benzyl-6-trifluoromethyl-1,3-dihydroimidazo[4,5-c]pyridin-2-one 
• 947144-20-9 1-benzyl-4-chloro-6-trifluoromethyl-1,3-dihydro-imidazo[4,5-c]pyridine-2-one 
• 947143-86-4 1-Benzyl-4-benzylamino-6-trifluoromethyl-1,3-dihydro-imidazo[4,5-c]pyridine-2-one 
• 1351804-32-4 C₁₃H₁₁F₃N₄O₂ 
• 1351804-33-5 C₁₃H₁₃F₃N₄ 
• 947144-36-7 benzyl-(2-chloro-3-nitro-6-trifluoromethylpyridin-4-yl)carbamic acid ethyl ester 
• 947144-34-5 (2-amino-3-nitro-6-trifluoromethylpyridin-4-yl)benzylcarbamic acid ethyl ester 
• 1303438-95-0 5-amino-1-benzyl-7-(trifluoromethyl)pyrido[4,3-b]pyrazine-2,3(1H,4H)-dione 
• 1303438-94-9 1-benzyl-5-bromo-7-(trifluoromethyl)pyrido[4,3-b]pyrazine-2,3(1H,4H)-dione 
• 1303438-93-8 N₄-benzyl-2-bromo-6-(trifluoromethyl)pyridine-3,4-diamine 
• 1303438-92-7 N-benzyl-2-bromo-3-nitro-6-(trifluoromethyl)pyridin-4-amine 

Relevant academic research and scientific papers

COMPOUNDS AND COMPOSITIONS AS TLR-7 ACTIVITY MODULATORS

The invention provides compounds, immunogenic compositions and pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with Toll-Like Receptors 7. In one aspect, the compounds are useful as adjuvants for enhancing the effectiveness of a vaccine.

Development of a practical synthesis of Toll-like receptor agonist PF-4171455: 4-amino-1-benzyl-6-trifluoromethyl-1,3-dihydroimidazo [4,5-c] pyridin-2-one

The development and implementation of a scalable process for the manufacture of the Toll-like receptor (TLR7) agonist PF-4171455 (1) is described. Initial routes used to synthesise 1 in milligram quantities were unsuitable for large-scale synthesis to pro

SPRAY DRIED FORMULATION

Pharmaceutical compositions comprising a poorly water soluble ionizable drug, a cationic species and a dispersion polymer are disclosed, together with a process for forming the compositions. The neutral form of the drug has (i) a solubility of less than 1 mg/mL in aqueous solution at a pH between 6 and 7, (ii) a solubility of less than 20 mg/mL in a volatile organic solvent, and (iii) an acidic pKa value of greater than 5. At least 90 wt% of the drug in the solid dispersion being in a non-crystalline form. The drug, the cationic species, and the dispersion polymer constitute at least 80 wt% of the solid dispersion.

NOVEL PHARMACEUTICALS

The present invention relates to immune response modifiers of formula (I), which act selectively through agonism, of Toll-Like Receptors (TLRs), uses thereof, processes for the preparation thereof, intermediates used in the preparation thereof and compositions containing said inhibitors. These inhibitors have utility in a variety of therapeutic areas including the treatment of infectious disease such as Hepatitis (e.g. HCV, HBV), genetically related viral infection and cancer.